medigraphic.com
ISSN 1025-0255 (Electronic)

2017, Number 1

<< Back Next >>

AMC 2017; 21 (1)

Mycobacterium tuberculosis vaccine candidates: an update on the topic

Torres TK, Ruiz HZ, Quesada LL

Language: Spanish
References: 38
Page: 877-891
PDF size: 492.39 Kb.


ABSTRACT

Background: the effectiveness of the current vaccine against tuberculosis is useful to counteract the lung forms of the disease. Its reactivation is variable or hardly efficient, which calls for an urgent search for new prophylactic alternatives against the infection. The progress on obtaining new drugs and vaccine depends largely on knowledge about the characteristics of the microorganism as well as immune response according to the pathogenic agent.
Objective: to carry out an updated revision of vaccine candidates against Mycobacterium tuberculosis in medical databases.
Methods: a bibliographic review of 60 articles published in databases was conducted. Among them, 40 were selected from the last decade, in order to undertake the research. Most studied subjects were analyzed regarding the pathogenic agent, Mycobacterium tuberculosis, vaccine candidate, and action mechanisms about the immune system. Types of vaccines and particular therapeutic potential for Mycobacterium tuberculosis apart from assessing the immunologic reaction with respect to vaccine candidate were revised in depth.
Conclusions: simulation of the infection and events that come after during natural immunity without causing the disease are essential conditions of a classical vaccine.


REFERENCES

  1. Herrera León L, Pozuelo Díaz R, Molina Mo-reno T, Valverde Cobacho A, Saiz Vega P, Jimé-nez Pajares MS. Aplicación de métodos molecu-lares para la identificación de las especies del complejo Mycobacterium tuberculosis. Enferm Infecc Microbiol Clin [Internet]. Nov 2009 [citado 12 Jun 2016];27(9):[aprox. 12 p.]. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=3658811

  2. Parida SK, Kaufmann SH. Novel tuberculosis vaccines on the horizon. Curr Opin Immunol. 2010 Jun;22(3):374-84

  3. Dirección Nacional de Registros Médicos y Es-tadísticas de Salud. Cuba. Anuario estadístico de salud 2009. La Habana: MINSAP; 2010. Compor-tamiento de la tuberculosis en Cuba; p. 32.

  4. Dirección Nacional de Registros Médicos y Es-tadísticas de Salud. Cuba. Anuario estadístico de salud 2010. La Habana: MINSAP; 2011. Compor-tamiento de la tuberculosis en Cuba; p. 22.

  5. Brennan M, Stone M, Evans T. A rational vac-cine pipeline for tuberculosis. Int J Tuberc Lung Dis. 2012 Dec;16(12):1566-73.

  6. Chegou N, Heyckendorf J, Walzl G, Lange C, Ruhwald M. Beyond the IFN-γ horizon: bi-omarkers for immunodiagnosis of infection with Mycobacterium tuberculosis. Eur Respir J. 2014 May;43(5):1472-1486.

  7. Mwaba P, McNerney R, Grobusch M, O'Grady J, Bates M, Zulma A, et al. Achieving STOP TB Partnership goals: perspectives on development of new diagnostics, drugs and vaccines for tuber-culosis. Trop Med Int Health. 2011 Jul;16(7):819-27.

  8. Hatherill M, Verver S, Mahomed H; Taskforce on Clinical Research Issues, Stop TB Partnership Working Group on TB Vaccines. Consensus state-ment on diagnostic end points for infant tubercu-losis vaccine trials. 2012 Feb 15;54(4):493-501.

  9. Kaboru B, Uplekar M, Lönnroth K. Engaging informal providers in TB control: what is the po-tential in the implementation of the WHO Stop TB Strategy? A discussion paper. World Health Popul. 2011;12(4):5-13.

  10. Pérez Arellano JL, Sánz Peláez O, Hernández Cabrera M, Moreno Maroto A. Situación actual y perspectivas clínicas de la tuberculosis. Proble-mas terapéuticos. Enf Emerg [Internet]. 2009 [citado 12 Jun 2016];7(1):[aprox. 9 p.]. Dispo-nible en www.researchgate.net/profile/Michele_Hernandez-Cabrera/publica-tion/255647480_Situacion_actual_y_perspectivas_clinicas_de_la_Tuberculosis_Problemas_terapeuticos/links/54bee0480cf28ad7e7196594

  11. Abbas AK, Lichtman AH, Pober JS. Inmunolo-gía celular y molecular. 6ta ed. Barcelona: Else-vier; 2008.

  12. Kumar M, Khan FG, Sharma S, Kumar R, Faujdar J, Sharma R, et al. Identification of My-cobacterium tuberculosis genes preferentially expressed during human infection. Microb Pathog. 2011 Jan;50(1):31-8.

  13. Iseman MD, Heifets LB. Rapid Detection of Tuberculosis and Drug-Resistant Tuberculosis. N Engl J Med. 2006;355(3):1606-07.

  14. van Ingen J, Boeree MJ, van Soolingen D, Iseman MD, Heifets LB, Daley CL. Are phyloge-netic position, virulence, drug susceptibility and in vivo response to treatment in mycobacteria interrelated?. Infect Genet Evol. 2012 Jun;12(4):832-7.

  15. van Ingen J, de Lange WC, Boeree MJ, Ise-man MD, Daley CL, Heifets LB, et al. XDR tuber-culosis. Lancet Infect Dis. 2011 Aug;11(8):585.

  16. Gandhi NR. Extensively drug-resistant tuber-culosis as a cause of death in patients coinfected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368(2):1575–80.

  17. Walls G, Bulifon S, Breysse S, Daneth T, Bonnet M, Hurtado N, et al. Drug-resistant tu-berculosis in HIV-infected patients in a national referral hospitalPhnom Penh, Cambodia. Glob Health Action [Internet]. 2015 Jan [citado 2015 Mar 16];8:[about 6 p.]. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/25623609

  18. Rada E, Aranzazu N, Convit J. Immune re-sponse of Hansen's disease. Invest Clin [Internet]. 2009 Dec [citado 2015 Mar 16];50(4):[about 15 p.]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20306725

  19. Albuquerque RG, Okazaki KM, Hirotsu C, To-mimori J, Tufik S, Andersen ML. Sleep, Hansen's disease and the immune system - A not so harmonic triad. Med Hypotheses [Internet]. 2015 May [cited 2015 Jun 16];84(5):[about 4 p.]. Available from: http://preview.ncbi.nlm.nih.gov/pubmed/25686506

  20. Aziz BA, Jeddane L, Ailal F, Benhsaien I, Mahlaoui N, Casanova JL, et al. Primary Immu-nodeficiency Diseases Worldwide: More Common than Generally Though. J Clin Immunol. 2013;33(1):1–7.

  21. Jepsen DF, Range N, Praygod G, Jeremiah K, Aabye MG, Changalucha J, et al. The use of com-bined heart rate response and accelerometry to assess the level and predictors of physical activi-ty in tuberculosis patients in Tanzania. Epidemiol Infect. 2014 Jun;142(6):1334-42.

  22. Stifter SA, Feng CG. Interfering with Immun-ity: Detrimental Role of Type I IFNs during Infec-tion. J Immunol [Internet]. 2015 [citado 2015 Jun 16];194(6):[about 10 p.]. Available from: http://www.jimmunol.org/content/jimmunol/194/6/2455.full.pdf

  23. Olivares Arzuaga N, Vila Infiesta A, Moya Torres A, Sarmientos Ramírez ME, Acosta Do-mínguez A, Norazmi MN. Papel de los anticuer-pos en la protección contra Mycobacterium tu-berculosis. VacciMonitor [Internet]. 2006 [citado 16 Jun 2015];15(3):[aprox. 5 p.]. Disponible en: http://scielo.sld.cu/pdf/vac/v15n3/vac04306.pdf

  24. Álvarez Cabrera N, Fernández Castillo S, Serpa Almaguer D, Serrano Hernández D, Zayas Vignier C, Cabrera Arias RA, et al. Avances en la caracterización de un proteoliposoma derivado de Mycobacterium bovis BCG como candidato vacunal contra la tuberculosis. Vaccimonitor [Internet]. Dic 2014 [citado 16 Mar 2015];23(3):[aprox. 6 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2014000300005

  25. Achkar JM, Casadevall A. Antibody-mediated immunity against tuberculosis: implications for vaccine development. Cell Host & Microbe. 2013 Mar;13(3):250-62.

  26. Ai W, Yue Y, Xiong S, Xu W. Enhanced pro-tection against pulmonary mycobacterial chal-lenge by chitosan-formulated polyepitope gene vaccine is associated with increased pulmonary secretory IgA and gamma-interferon(+) T cell responses. Microbiol Immunol [Internet]. 2013 Mar [citado 2015 Mar 16];57(3):[about 11 p.]. Available from: http://onlinelibrary.wiley.com/doi/10.1111/1348-0421.12027/full

  27. Kolibab K, Yang A, Steven CD, Waldmann TA, Perera L, Morris SL. Highly Persistent and Effective Prime/Boost Regimens against Tuber-culosis That Use a Multivalent Modified Vaccine Virus Ankara-Based Tuberculosis Vaccine with Interleukin-15 as a Molecular Adjuvant. Clin Vac-cine Immunol [Internet]. 2010 May [citado 2015 Mar 16];17(5):[about 8 p.]. Available from: http://cvi.asm.org/content/17/5/793.full.pdf+html

  28. Shin DM, Jeon BY, Lee HM, Jin HS, Yuk JM, Song CH, et al. Mycobacterium tuberculosis Eis Regulates Autophagy, Inflammation, and Cell Death through Redox-dependent Signaling. PLoS Pathogens [Internet]. 2010 [citado 2015 Mar 16];6(12):[about 12 p.]. Available from: http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1001230

  29. Kolibab K, Smithson SL, Rabquer B, Khuder S, Westerink MA. Immune response to pneumo-coccal polysaccharides 4 and 14 in elderly and young adults: analysis of the variable heavy chain repertoire. Infect Immun [Internet]. 2005 Nov [citado 2015 Mar 16];73(11):[about 11 p.]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1273876/.

  30. Hernández Pando R. Nuevas vacunas contra Tb. Salud pública méx [Internet]. 2007 [citado 16 Mar 2015];49:[aprox. 6 p.]. Disponible en: http://www.redalyc.org/articulo.oa?id=10649079

  31. Marrón González R. Potencial de los liposo-mas de Mycobacterium smegmatis como candi-dato vacunal frente a la tuberculosis [tesis]. La Habana: Universidad de Ciencias Médicas de La Habana; 2010.

  32. SF Martin. Adaptation in the innate immune system and heterologous innate immunity. Cell Mol Life Sci [Internet]. 2014 Nov [citado 2015 Mar 16];71(21):[about. 15 p.]. Available from: http://link.springer.com/article/10.1007%2Fs00018-014-1676-2

  33. Daniels K, Hatfield S, Welsh R, Brehm M. MHC basis of T cell-dependent heterologous im-munity to arenaviruses. Virology [Internet]. 2014 Sep [citado 2015 Mar 16];0:[about 4 p.]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196705/.

  34. Nguyen LT, Borrero Maura R, Fernández Cas-tillo S, Reyes Álvarez G, Pérez Arellano JL, Gar-cía Santana MA, et al. Evaluation of the potential of Mycobacterium smegmatis as vaccine Candi-date against tuberculosis by in silico and in vivo studies. Vaccimonitor. 2010 Apr;19(1):20-6.

  35. Addine Ramírez B, Marrón González R, Cale-ro Ramos R, Mirabal Sosa M, Ramírez de la Cruz JC, Sarmiento García ME, et al. In sílico identifi-cation of common epitopes from pathogenic my-cobacteria. BMC Immunology [Internet]. 2013 [citado 2015 Mar 16];14(1):[about. 5 p.]. Avail-able from: bmcim-track/pdf/10.1186/1471-2172-14-S1-S6?site=bmcimmunol.biomedcentral.com

  36. Valdés Hernández I, Echemendía Font M, Mederos Cuervo L, Valdivia Álvarez JA, Montoro Cardoso E. Aspectos relevantes del uso de Myco-bacterium´habana´ como candidato vacunal contra la tuberculosis. Vaccimonitor. 2011 Dic;20(3):34-39.

  37. Jae MY, Eun KJ. Host immune responses to mycobacterial antigens and their implications for the development of a vaccine to control tubercu-losis. Clin Exp Vaccine Res [Internet]. 2014 Jul [citado 2015 Mar 16];3(2):[about. 18 p.]. Avail-able from: http://synapse.koreamed.org/DOIx.php?id=10.7774/cevr.2014.3.2.155

  38. Velásquez J. Tuberculosis extrapulmonar en niños. Neumol Pediatr [Internet]. Mar 2015 [citado 16 Mar 2015];10(4):[aprox. 9 p.]. Dispo-nible en: http://www.neumologia-pediatrica.cl/PDF/2015104/tuberculosis-extrapulmonar.pdf




2020     |     www.medigraphic.com